Parsaclisib plus ruxolitinib to treat myelofibrosis improves spleen size and symptom burden

According to the results of a phase 2 study, presented during the American Association for Cancer Research 2021 Annual Meeting, patients with myelofibrosis—with a previous suboptimal response to ruxolitinib monotherapy—who were treated with PI3Kδ inhibitor parsaclisib 5 to 20 mg daily for 8 weeks, then 5 mg daily thereafter, plus ruxolitinib experienced greater reduction in spleen volume (-15.4%), compared with patients receiving 10 to 20 mg daily for 8 weeks and then weekly parsaclisib (-2.3%). More of the daily dosed group also had 50% or greater symptom reduction at weeks 12 (31%) and 24 (17%) vs. the daily/weekly dosing group (15% and 4%, respectively).